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Abstract
Background: Human b-defensin-2 (HBD2) is an antimicrobial peptide implicated in the pathogenesis of inflammatory bowel
disease (IBD). Low copy number and concomitant low mRNA expression of the HBD2 gene have been implicated in
susceptibility to colonic Crohn’s Disease (CD). We investigated the colonic distribution of HBD2 mRNA expression, and the
contributions of genetic and environmental factors on HBD2 protein production.
Methodology/Principal Findings: We examined HBD2 mRNA expression at three colonic locations by microarray analysis of
biopsies from 151 patients (53 CD, 67 ulcerative colitis [UC], 31 controls). We investigated environmental and genetic
influences on HBD2 protein production using ex vivo cultured sigmoid colon biopsies from 69 patients (22 CD, 26 UC, 21
controls) stimulated with lipopolysaccharide (LPS) and/or nicotine for 24 hours. HBD2 and cytokines were measured in
culture supernatants. Using DNA samples from these patients, regions in the HBD2 gene promoter were sequenced for NF-
kB binding-sites and HBD2 gene copy number was determined. HBD2 mRNA expression was highest in inflamed (vs.
uninflamed p= 0.0122) ascending colon in CD and in inflamed (vs. uninflamed p,0.0001) sigmoid colon in UC. HBD2
protein production was increased in inflamed UC biopsies (p = 0.0078). There was no difference in HBD2 protein production
from unstimulated biopsies of CD, UC and controls. LPS-induced HBD2 production was significantly increased in CD
(p = 0.0375) but not UC (p = 0.2017); this LPS-induced response was augmented by nicotine in UC (p = 0.0308) but not CD
(p = 0.6872). Nicotine alone did not affect HBD2 production. HBD2 production correlated with IL8 production in UC
(p,0.001) and with IL10 in CD (p,0.05). Variations in the HBD2 promoter and HBD2 gene copy number did not affect HBD2
production.
Significance/Conclusions: Colonic HBD2 was dysregulated at mRNA and protein level in IBD. Inflammatory status and
stimulus but not germline variations influenced these changes.
Citation: Aldhous MC, Noble CL, Satsangi J (2009) Dysregulation of Human b-Defensin-2 Protein in Inflammatory Bowel Disease. PLoS ONE 4(7): e6285.
doi:10.1371/journal.pone.0006285
Editor: Stefan Bereswill, Charite´-Universita¨tsmedizin Berlin, Germany
Received May 27, 2009; Accepted June 10, 2009; Published July 20, 2009
Copyright:  2009 Aldhous et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by grants from the National Association for Crohn’s and Colitis (M/02/6 to JS) and the Chief Scientist’s Office of the Scottish
Government (CBZ/4/68 to JS). The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: maldhous@ed.ac.uk
Introduction
The inflammatory bowel diseases (IBD), Crohn’s disease (CD)
and ulcerative colitis (UC) are common causes of chronic disease
in the developed world and represent an important public health
issue, with a combined prevalence in northern Europe estimated at
1 in 250 [1]. The incidence and prevalence of both adult and early
onset disease is particularly high in Scotland [2] affecting quality of
life and employment potential in adults as well as growth and
education in children.
Considerable recent progress has been made in understanding
the pathogenesis of IBD. A number of susceptibility genes have
been identified [3,4] highlighting important pathogenic mecha-
nisms, notably the innate immune response in CD. Additionally,
there is now unequivocal evidence regarding the identity of
environmental influences involved in the pathogenesis of IBD,
with consistent data implicating the gut flora, as selective changes
in bacterial populations have been demonstrated in patients with
different phenotypes of CD [5,6].
Smoking is the best known environmental factor implicated in
the pathogenesis of IBD [7]. We and others have illustrated that
smoking habit strongly affects the disease history of both CD [8–
10] and UC [11,12]. Of the.4000 chemicals in cigarette smoke,
nicotine has been studied as a constituent potentially affecting
intestinal inflammation. Studies of transdermal nicotine therapy
suggest that this may be effective in UC patients with active disease
[13,14]. However, the mechanisms whereby nicotine may
influence intestinal inflammation are poorly characterised and
there have been few studies of the effects of nicotine on the cellular
responses of IBD patients, especially in CD. In mouse models of
IBD, nicotine had differential effects on the small and large bowel
[15,16], with increased jejunal inflammation and decreased
colonic inflammation together with inhibition of pro-inflammatory
cytokines [17].
The interest in the innate immune response in disease
pathogenesis has led to evaluation of the role of defensins, part
of a family of anti-microbial peptides with direct bactericidal
activity against a wide variety of bacteria [18]. In man, a-
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defensins, HD-5 and HD-6 are expressed in small-bowel Paneth
cells [19]. Production of a-defensins is dysregulated in CD [20–
22], and we have also demonstrated them to be up-regulated in
UC due to Paneth cell metaplasia [23]. The human b-defensins
(HBDs) are expressed in various tissues throughout the body, with
HBD1, HBD2 and HBD3 expressed in the gut [24]. Studies at the
mRNA level, have shown that HBD1 is normally constitutively
expressed but reduced in CD and UC patients and that both
HBD2 and HBD3 are induced with inflammation in CD and UC
[25,26]. Other studies have indicated that probiotic bacteria
induce HBD2 production in intestinal epithelial cells via NF-kB,
leading to increased barrier function in the gut [27,28]. Taken
together these data suggest that b-defensins, in particular HBD2,
may have a key role in determining innate immune responses to
bacteria in the gut.
Genetic factors have also been implicated in HBD2 protein
production. Defensins, on chromosome 8p23, have been found to
be polymorphic for copy number [29,30]. Recent work has shown
an association between high copy number of the HBD2 gene
DEFB4 and risk of psoriasis, suggesting that HBD2 may be
associated with an inappropriate inflammatory response in the skin
[31]. As HBD2 production has been shown to be abrogated by
deletion of NF-kB binding sites in the DEFB4 promoter region
[28], the relative contribution of inflammation, perhaps via
activation of NF-kB in IBD [32] is potentially important in the
regulation of HBD2 production. In the only study to date of IBD
patients, Fellerman et al., suggested that low copy number of the
HBD2 gene, DEFB4, predisposed to colonic disease [33] and that
copy number was associated with levels of mRNA expression in
inflamed rectal biopsies. However, these data have not been
independently replicated and the relationship between DEFB4
copy number and HBD2 protein production has not been
investigated in IBD.
In this study, we initially mined microarray expression data [23]
previously obtained from our Scottish patient population and
showed that expression of HBD2 mRNA changed with disease,
inflammation and colonic location. We then investigated produc-
tion of HBD2 protein from biopsies in ex vivo organ culture and
assessed the effects of environmental factors, such as inflammation
status and stimulus (bacterial lipopolysaccharide [LPS] and/or
nicotine) and genetic factors (NF-kB binding sites and DEFB4
copy number) that might affect this production. Our results show
that inflammation and stimulation had more of an effect on HBD2
production than these genetic factors.
Materials and Methods
Ethics statement
The Medicine and Oncology Subcommittee of the Lothian
Local Research Ethics Committee approved the study protocol
(LREC 2001/4/72).
Patients and controls
Full details of the patients involved in the microarray analysis
are given elsewhere [23] (and Noble 2009, submitted to Gut). Data
were used of biopsies taken from 3 colonic locations (ascending,
descending or sigmoid colon) from patients with CD (83 biopsies
from 53 patients), UC (124 biopsies from 67 patients) or controls
(66 biopsies from 31 patients). Of the controls, 23 had
histologically normal biopsies, while 8 had inflamed colonic
biopsies as defined from a paired biopsy graded by an experienced
gastrointestinal pathologist as having no evidence of inflammation,
or with evidence of acute/chronic inflammation and/or acute/
chronic inflammatory cell infiltrate.
For the ex vivo organ culture studies, IBD patients (22 CD, 26
UC) underwent routine colonoscopy indicated in their clinical
management at the Western General Hospital, Edinburgh,
Scotland. The diagnosis of IBD adhered to Lennard-Jones criteria
[34]. Age at diagnosis and disease phenotype (location and
behaviour for CD, disease extent for UC) were classified according
to the Montreal classification [35]. Phenotypic data were collected
by patient questionnaire, interview and casenote review and were
composed of demographics, dates of onset and diagnosis, disease
location/extent, disease behaviour, surgical operations, smoking
history and family history. Controls (n = 21) for these experiments
were patients undergoing endoscopy for investigation of conditions
not related to IBD, but who were otherwise healthy, e.g.
surveillance colonoscopy for family history of colon cancer, or
previous polyps. These subjects also gave a blood sample from
which DNA was extracted and were included in the genetic
analysis. All patients and controls gave informed, written consent.
The demographics and disease characterisation of the patients and
controls are shown in table 1.
Biopsies were obtained from the sigmoid colon. DNA samples
obtained from blood [36] were available for 61 of these patients
(20 CD, 24 UC and 17 HC).
Organ culture method
Colonic pinch biopsies obtained at endoscopy were placed with
luminal surface face up, on sterile metal grids over a central well of
an organ culture dish (Falcon, UK), with the biopsies were at the
liquid-air interface. The central well contained 2 ml Waymouth’s
medium (Gibco, UK) containing 100 U/ml penicillin (Sigma,
UK), 100 mg/ml streptomycin (Sigma, UK), 50 mg/ml Gentami-
cin (Sigma, UK), 10% foetal calf serum (Gibco, UK), 300 mg/ml
Ascorbic acid (Sigma, UK). Nicotine alone (1, 10, 100 mg/ml,
Sigma, UK), LPS alone (1 mg/ml, from Escherichia coli B4:111),
Sigma, UK) or nicotine and LPS together (100 and 1 mg/ml,
respectively) were added to the medium in the dish and there was
a medium only control. The doses of nicotine and LPS were those
we have used previously [37]. Biopsies were incubated in a
modular incubator chamber in a humidified atmosphere of 95%
oxygen and 5% carbon dioxide under slight pressure. The time
from collecting biopsies and placing them in culture was usually
within 30 minutes. Biopsies were cultured for 24 hours, when the
culture supernatants were collected and stored at 280uC for later
analysis of HBD2 and cytokines (TNFa, IL1b, IL8 and IL10).
HBD2 and cytokine analysis in supernatants
HBD2 was analysed in culture supernatants using a matched
antibody pairs ELISA development kit (Peprotech, UK), according
to manufacturer’s instructions. TNFa, IL1b, IL8 and IL10 were
also measured using matched antibody pair ELISA kits (Duosets,
R&DSystems, UK), according to manufacturer’s instructions.
Sequencing of DEFB4 promoter region
The promoter region (,1000 bp) of the DEFB4 gene was
investigated in 44 patient samples (14 CD, 16 UC and 14 HC).
Potential NF-kB binding sites were identified in this region by the
Transcription Element Search System (TESS) [38], which gave
sites at 2582 to 2572 bp and 2236 to 2225 bp. Sites have also
been described previously at positions 2596 to 2572 bp and
2205 to 2186 bp[39]. Primers spanning the region including all
these sites were: forward primers AATCCCATCCTCCCATTCTC
and TTTCACCAGCTCAGATCTCC; reverse primers GGAGA-
TACAAGACCCTCATGG and CGAGAAGAGGAGATACAA-
GACCC. The PCR product was sequenced on an ABI Genetic
Analyser at the MRC Human Genetics Unit, Edinburgh.
Dysregulated HBD2 in IBD
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Table 1. Patient demographics, disease characteristics and NOD2 genotype.
Demographic parameter Subject Group
CD UC Controls
N=22 N=26 N=21
Sex (M:F) 5:17 14:12 8:13
Age (years): Median (range)
At diagnosis 34.6 (10.4–71.6) (10.3–79.7) NA
At sampling 45.6 (25.9–74.6) 46.9 (18.9–80.9) 54.0 (22.2–80.6)
Disease duration 9.75 (0.18–35.1) 2.07 (0.03–27.4) NA
Positive Family History of IBD N (%) 4 (18.2) 7 (28.0) 0 (0)
Disease location/extent* N (%)
CD Location NA NA
Ileal disease (L1){ 7 (31.8)
Colonic disease (L2) 11 (50.0)
Ileo colonic (L3) 3 (13.6)
Unknown 1 ( 4.6)
CD Behaviour NA NA
Inflammatory 12 (54..5)
Stricturing 7 (31.8)
Penetrating 2 ( 9.1)
Any penetrating perianal 4 (18.2)
Unknown 1 ( 4.6)
UC Disease Extent NA NA
Rectal disease (E1) 2 ( 7.7)
Left-sided disease (E2) 11 (42.3)
Extensive disease (E3) 11 (42.3)
Unknown 2 ( 7.7)
Surgery prior to time of biopsy{ N (%) NA
Yes 10 (45.4) 2 ( 7.7)
No 11 (50.0) 23 (88.5)
Unknown 1 ( 4.6) 1 ( 3.8)
Disease activity{{ N (%) NA
Active/inflamed 7 (31.8) 13 (50.0)
Mildly inflamed 2 ( 9.1) 6 (23.1)
Inactive/uninflamed 13 (59.1) 7 (26.9)
Smoking habit at Sampling
Current 8 (36.4) 5 (19.2) 4 (19.0)
Non 5 (22.7) 12 (46.2) 4 (19.0)
Ex 9 (40.9) 9 (34.6) 5 (23.8)
Unknown 0 0 8 (38.2)
NOD2 mutation carriage{{ (N %)
Any of R702W, G908R, 1007fs 4 (18.2) 2 ( 7.7) 2 ( 9.5)
None 16 (72.7) 22 (84.6) 16 (76.2)
Unknown 2 (9.1) 2 ( 7.7) 3 (14.3)
*Disease location/extent defined according to the Montreal Classification[35].
{One patient had upper GI disease with L1.
{Surgery was resection for CD, hemi-colectomy for UC.
{{Disease activity as reported in pathology report.
{{NOD2 genotyping was carried out as previously described[36]. NA – not applicable.
doi:10.1371/journal.pone.0006285.t001
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Determination of DEFB4 copy number
DEFB4 genomic copy number was measured using established
paralogue ratio testing (PRT) methods [40,41] with modifications
(Professor John Armour, personal communication) at the School of
Biology, University of Nottingham.
Statistical Analyses
Statistical tests were carried out using GraphPad PrismH version 4
(GraphPad Software, SanDiego, CA, USA). Significance was defined
at p,0.05. Comparisons of the microarray data used Kruskall-Wallis
test with post-hoc Dunn’s test for multiple comparisons or Mann
Whitney tests. Comparison of unstimulated, LPS- and LPS+nicotine-
stimulated HBD2 protein results between disease groups used
Friedman tests or Wilcoxon signed rank tests. Comparisons across
stimuli and/or disease groups were carried out using a two-way
ANOVA. Correlations between cytokines and HBD2 production
used a Spearman non-parametric correlation test.
Results
Expression of HBD2 mRNA throughout colon
To investigate HBD2 mRNA expression throughout the colon
we mined the microarray data and found that the expression of
HBD2 mRNA differed according to disease group (figure 1A),
inflammation (figure 1B) and location in the colon (figure 1C).
HBD2 expression is shown as the log2 mRNA expression relative
to a control reference marker [23].
Effect of disease group. When biopsies from CD, UC
patients and controls were compared, we found a significant
difference (Kruskall-Wallis, p = 0.0028, figure 1A) driven by the
differences between UC and controls (post-hoc Dunn’s test,
p,0.01). When CD biopsies were compared with controls,
HBD2 mRNA was slightly but not quite significantly increased
in CD patients (CD: mean=1.550, median = 1.183, IQR 1.080–
1.373 vs. controls mean= 1.157, median= 1.137, IQR 1.075–
1.223, Mann-Whitney p= 0.0516). Comparison of UC and
controls showed increased HBD2 expression in UC (UC
mean= 1.808, median= 1.206, IQR 1.124–1.420, Mann-
Whitney vs. controls p = 0.0004).
Effect of inflammation. When inflamed and uninflamed
biopsies were compared, we found that for all three groups HBD2
mRNA expression was increased with inflammation (figure 1B;
CD inflamed: mean= 1.952, median= 1.321, IQR 1.135–2.580
vs. CD uninflamed: mean=1.138, median = 1.113, IQR 1.051–
1.239, Mann-Whitney p,0.0001; UC inflamed: mean= 2.265,
median = 1.330, IQR 1.171–1.761 vs. UC uninflamed:
mean= 1.272, median= 1.156, IQR 1.076–1.257, Mann-
Whitney p,0.0001; control inflamed: mean=1.230,
median = 1.247, IQR 1.116–1.313 vs. control uninflamed:
mean= 1.131, median= 1.126, IQR 1.048–1.203, Mann-
Whitney p= 0.0066). There were no differences when inflamed
and uninflamed biopsies from the three groups were compared
(Kruskall-Wallis inflamed p= 0.1215, uninflamed p= 0.2932).
Effect of colonic location. For inflamed biopsies from both
CD and UC patients we found a differential gradient of HBD2
mRNA expression: in CD, the mean and median expression was
highest in biopsies obtained from the ascending colon (mean=2.316,
median=1.716, IQR 1.221–3.535), then descending colon
(mean=2.050, median=1.530, IQR 1.251–3.042) with the lowest
expression in sigmoid colon (mean=1.593, median=1.201, IQR
1.049–1.352); in UC the opposite pattern was seen with the lowest
expression in the ascending colon (mean=1.265, median=1.234,
IQR 1.049–1.328) then descending colon (mean=2.043,
median=1.332, IQR 1.130–1.755) and highest expression in the
sigmoid colon (mean=2.735, median=1.405, IQR 1.200–2.107). A
gradient of expression was not seen in inflamed biopsies from control
patients: ascending colon (mean=1.267, median=1.265, IQR
1.1890–1.345), descending colon (mean=1.225, median=1.220,
IQR 1.103–1.354) and sigmoid colon (mean=1.213,
median=1.247, IQR 1.100–1.301). HBD2 mRNA expression in
inflamed sigmoid biopsies was higher in UC compared with controls
(Mann-Whitney p=0.0364).
In organ culture, HBD2 protein was increased by LPS
alone in CD and UC but not controls, and further
increased by addition of nicotine in UC
HBD2 production was measured in supernatants of unstimu-
lated and stimulated biopsies from IBD patients and controls
(figure 2). There was no difference in unstimulated HBD2
production between CD and UC patients and controls (CD
unstimulated: mean= 21.45, median= 7.02, IQR 0–31.1 pg/ml;
UC unstimulated: mean= 32.14, median= 8.892, IQR 0–
43.0 pg/ml; control unstimulated: mean= 20.51, median = 8.64,
IQR 0–37.1 pg/ml; Kruskall-Wallis p = 0.855).
In CD, LPS significantly induced HBD2 production from the
biopsies (unstimulated: mean=21.45, median= 7.02, IQR 0–
31.1 pg/ml; LPS: mean= 41.07, median= 13.1, IQR 0.99–
52.4 pg/ml Wilcoxon signed rank test p = 0.0375, figure 2). The
increased production of HBD2 by LPS was not sustained by
addition of nicotine (LPS+nicotine: mean=26.34, median = 8.11,
IQR 0–36.4 pg/ml, unstimulated vs. LPS+nicotine: Wilcoxon
signed rank test p= 0.6872).
For UC, LPS increased production of HBD2 from biopsies but
this was not significant in comparison to unstimulated biopsies
(unstimulated: mean=32.14, median= 8.892, IQR 0–43.0 pg/ml;
LPS: mean=68.41, median= 4.68, IQR 0–59.5 pg/ml, Wilcoxon
signed rank test p= 0.2017). In UC, addition of nicotine to LPS
further increased HBD2 production, which was significantly
different from unstimulated biopsies (LPS+nicotine: mean=81.73,
median= 9.65, IQR 0–57.7 pg/ml, unstimulated vs. LPS+nicotine:
Wilcoxon signed rank test, p = 0.0308, figure 2) and almost
significantly different from stimulation with LPS alone (Wilcoxon
signed rank test LPS vs LPS+nicotine p= 0.0786).
For controls there was no significant induction of HBD2
production on stimulation with LPS (unstimulated: mean=20.51,
median= 8.64, IQR 0–37.1 pg/ml; LPS: mean=25.51, medi-
an= 16.2, IQR 0–35.0 pg/ml, Wilcoxon signed rank test
p= 0.5436). There was no further significantly increased production
of HBD2 on stimulation with LPS and nicotine (LPS+nicotine:
mean=31.15, median= 14.45, IQR 0–32.5 pg/ml, unstimulated
vs LPS+nicotine Wilcoxon signed rank test p= 0.5784, figure 2).
There was no difference in HBD2 production when biopsies were
stimulated with nicotine alone in CD or UC patients or controls.
HBD2 production was associated with inflammation in
UC but not CD
Comparison of HBD2 production by disease and inflammation
(figure 3) showed that disease and inflammation significantly
affected the levels of HBD2 produced (2-way ANOVA: disease/
disease activity p= 0.0078), with less from the uninflamed biopsies
of UC patients and the most from inflamed biopsies of UC
patients. In CD, there was no difference in the amount of HBD2
produced with inflammation, but the pattern of HBD2 production
differed: in inflamed biopsies HBD2 production in response to
LPS+nicotine was increased, similar to that seen in UC, whereas
in uninflamed biopsies it was reduced as previously noted when all
biopsies from CD patients were analysed together.
Dysregulated HBD2 in IBD
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Figure 1. Expression of HBD2 mRNA with disease (A), inflammation (B) and colonic location of inflamed biopsies (C). All graphs show
the log2 expression values from comparison with a reference marker (of value = 1) for HBD2 mRNA. Horizontal bars denote the median values for
each analysis. P values from Mann-Whitney or Kruskall-Wallis tests are given, where significantly different.
doi:10.1371/journal.pone.0006285.g001
Dysregulated HBD2 in IBD
PLoS ONE | www.plosone.org 5 July 2009 | Volume 4 | Issue 7 | e6285
HBD2 increased with degree of inflammation in UC
Further analysis of the HBD2 production in the sigmoid colon
of UC patients showed that HBD2 increased with degree of
inflammation; when disease activity of the samples was taken into
account for the protein production, inflammation status was
significantly different (p = 0.0169, two-way ANOVA, figure 4A).
Similarly, from the microarray data higher HBD2 mRNA
expression was shown in acutely inflamed biopsies (acute:
median = 1.76, IQR 1.19–4.15) and chronically inflamed biopsies
(chronic: median= 1.39, IQR 1.20–1.74) compared with unin-
flamed biopsies (uninflamed median = 1.14, IQR 1.03–1.25; acute
vs. uninflamed Mann-Whitney p= 0.0032; chronic vs. uninflamed
Mann-Whitney p= 0.0004, one-way ANOVA p=0.004 figure 4B).
Production of HBD2 differentially correlated with
production of cytokines
The results of correlations between HBD2 production and
cytokine production are presented in table 2. HBD2 positively
correlated with IL8 production in UC patients and HC but not in
CD patients. HBD2 production negatively correlated with IL1b in
uninflamed, unstimulated biopsies from CD patients (p = 0.0396),
but this was not seen in any other group.
HBD2 production positively correlated with IL10 production in
unstimulated and LPS-stimulated biopsies from CD patients but these
correlations were lost when inflammation status was taken into
account. Similarly HBD2 production from all LPS-stimulated biopsies
fromUC patients also correlated with IL10 production, but this did not
hold when inflammation status was taken into account. For HC,
HBD2 production from unstimulated biopsies correlated with IL10 but
not for LPS-stimulated biopsies. There was no correlation between
production of HBD2 and production of TNFa in any biopsies.
HBD2 production was not associated with disease
phenotype in CD or UC
There was no association in HBD2 production according to
location (two-way ANOVA p=0.376) or disease behaviour (two-
way ANOVA, p= 0.813) in CD patients. In UC, an association
with disease extent (two-way ANOVA p=0.0042) was explained
by the increased inflammation in the patients with most extensive
disease. For both CD and UC there was no association with need
for surgery (two-way ANOVA, p=0.232, p = 0.781, respectively).
There was no difference in HBD2 production according to
smoking habit at time of sampling in any disease group (two way
ANOVA for smoking habit, p = 0.760).
No correlation between polymorphisms in the NF-kB
binding sites and hBD2 production
HBD2 production has been shown to be abrogated by deletion
of NF-kB binding sites in the HBD2 promoter [28]. To investigate
further potential explanations for the increased HBD2 production
in response to LPS in CD and UC but not HC, we sequenced the
promoter region of the DEFB4 gene, to ask whether IBD patients
had polymorphisms at potential NF-kB binding sites, as identified
by Transcriptional Element Search Software (TESS) [38]. NF-kB
Figure 2. Production of HBD2 protein by LPS or LPS+nicotine in CD and UC patients and controls. HBD2 protein production (mean+sem)
from culture supernatants of unstimulated or LPS- or LPS+nicotine (denoted LN)-stimulated biopsies in organ culture. * denotes P values of,0.05
from the results of Wilcoxon signed rank tests and the groups compared are shown. The actual p values are given in Results.
doi:10.1371/journal.pone.0006285.g002
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recognises the consensus sequence GGGRNTYYCC [42]. For the
region between 2596 bp to 2572 bp, all patient sequences were
found to be the same as that found in Ensembl. For the regions
2236 to 2225 bp and 2205 to 2186 bp, variations in sequence
were found, but there was no polymorphism that changed the site
into the NF-kB binding site consensus sequence.
There was no significant difference in hBD2 production from
CD patients with sequence variations at any NF-kB binding sites
Figure 3. HBD2 production according to disease and inflammation status. HBD2 production (mean+sem) from biopsies from CD, UC
patients or controls, unstimulated or stimulated with LPS or LPS+nicotine (denoted LN) and grouped according to disease and inflammation. P value
given is from a two-way ANOVA compared by disease/inflammation or stimulation.
doi:10.1371/journal.pone.0006285.g003
Figure 4. Increased HBD2 with inflammation in UC sigmoid colon is seen in protein (A) and mRNA (B). (A) HBD2 protein production from
UC patients according to stimulation and inflammation status. Legend is as given for figure 3. The P value from a two-way ANOVA is given. (B) HBD2
mRNA expression for UC biopsies in sigmoid colon, grouped according to inflammation status[23]. Horizontal bars denote median values. P values
are from Mann-Whitney tests and the groups compared are indicated. The P value from a one-way ANOVA is also given.
doi:10.1371/journal.pone.0006285.g004
Dysregulated HBD2 in IBD
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(variants) than in those wild-type (WT) sequence (CD WT
unstimulated mean= 29.43, median= 0, IQR 0–58.86; CD WT
LPS mean= 12.62, median = 6.611, IQR 0–25.25; CD variants
unstimulated mean=20.55, median= 15.07, IQR 1.408–31.13;
CD variants LPS mean= 55.14, median = 35.15, IQR 4.750–
92.34, one-way ANOVA p=0.2493). In UC patients, any
differences in HBD2 production in the patients with WT
sequence compared with those with variant sequence, were not
significant (UC WT unstimulated mean= 30.53, median = 7.030,
IQR 0–66.17; UC WT LPS mean=91.94, median= 7.415, IQR
0–106.7; UC variants unstimulated mean= 7.304, medi-
an = 5.624, IQR 0–16.29; UC variants LPS mean=2.516,
median = 1.240, IQR 0–6.307, one-way ANOVA p=0.5867). In
HC patients, there were no differences in HBD2 production
between unstimulated and stimulated biopsies from patients with
variants or wild-type sequence (HC WT unstimulated
mean= 20.40, median = 0, IQR 0–11.26; HC WT LPS
mean= 21.74, median= 13.13, IQR 0–29.13; HC variants
unstimulated mean=17.16, median= 12.2, IQR 0–39.27; HC
variants LPS mean= 18.04, median= 16.53, IQR 1.318–36.28,
one-way ANOVA p=0.4956).
No difference in HBD2 production according to DEFB4
copy number
HBD2 protein production (unstimulated, LPS- and LPS+ni-
cotine-stimulated) from biopsies was compared by DEFB4 gene
copy number in patients and controls. As the median copy
number found in our patients was 4, biopsies were classed as,4
or $4 and results are shown in figure 5. No differences were
found with CNV and HBD2 production from unstimulated or
stimulated biopsies in any patient group (CD: Kruskall-Wallis
p = 0.4533, UC: Kruskall-Wallis p = 0.9413, HC Kruskall-Wallis
p = 0.9525). When biopsies from inflamed and uninflamed tissue
were each compared, the previously seen differential pattern of
response to LPS+nicotine in inflamed and uninflamed CD
biopsies was confirmed in this analysis but no differences were
seen (Kruskall-Wallis p = 0.5348). Similarly in UC, while
increased HBD2 protein was seen in inflamed biopsies, there
were no differences according to copy number (Kruskall-Wallis
p = 0.3905).
There was no significant correlation between copy number and
HBD2 production, even when inflammation was taken into
account.
Table 2. Correlations between HBD2 and IL1b, IL8 & IL10 production from unstimulated, LPS- and LPS+nicotine-stimulated
biopsies obtained from patients and controls.
Biopsies Correlation with IL1b Correlation with IL8 Correlation with IL10
Disease, stimulation
and inflammation Spearman r 95% CI p value Spearman r 95% C I p value Spearman r 95% CI p value
CD: unstimulated
All 0.0155 20.420–0.455 0.945 20.0885 20.586–0.457 0.754 0.429 20.004–0.727 0.0463
Inflamed 0.470 exact 0.213 0.0985 Exact 0.840 0.608 exact 0.0863
Uninflamed 20.575 20.860– 20.0173 0.0396 20.347 Exact 0.389 0.298 20.319–0.738 0.322
CD: LPS-stimulated
All 20.115 20.552–0.335 0.611 20.179 20.643–0.381 0.523 0.521 0.114–0.778 0.0129
Inflamed 0.259 exact 0.493 0.216 Exact 0.662 0.783 Exact 0.0172
Uninflamed 20.357 20.766–0.259 0.231 20.310 Exact 0.462 0.371 20.243–0.773 0.212
CD: LPS+nicotine stimulated
All 0.178 20.276–0.567 0.428 0.171 20.389–0.638 0.542 0.274 20.180–0.632 0.217
Inflamed 0.377 exact 0.313 0.0721 Exact 0.906 0.851 exact 0.0061
Uninflamed 20.0664 20.607–0.517 0.829 0.317 Exact 0.428 20.0724 20.611–0.512 0.814
UC: unstimulated
All 0.291 20.121–0.617 0.149 0.690 0.281–0.887 0.0031 0.261 20.153–0.597 0.198
Inflamed 0.374 20.111–0.715 0.115 0.890 0.634–0.970 0.0001 0.283 20.211–0.661 0.241
Uninflamed 20.0935 exact 0.840 0.738 exact 0.333 0.115 exact 0.840
UC: LPS-stimulated
All 0.130 20.282– 0.502 0.527 0.771 0.432–0.919 0.0005 0.456 0.0712–0.723 0.0192
Inflamed 0.071 20.409–0.519 0.774 0.947 0.810–0.986 ,0.0001 0.434 20.0403–0.748 0.0637
Uninflamed 0.0591 exact 0.906 0.775 exact 0.333 20.307 exact 0.498
UC: LPS+nicotine stimulated
All 0.234 20.181–0.578 0.251 0.808 0.531–0.937 0.0001 0.421 0.0285–0.701 0.0320
Inflamed 0.313 20.179–0.680 0.192 0.873 0.588–0.965 0.0002 0.489 0.0300–0.778 0.0337
Uninflamed 20.0371 exact 0.964 0.949 Exact 0.0833 20.231 exact 0.595
HC: unstimulated 0.0561 20.397–0.487 0.809 0.229 20.238–0.610 0.319 0.516 0.0948–0.781 0.0167
HC: LPS-stimulated 20.0589 20.489–0.394 0.799 0.607 0.224–0.827 0.0035 0.294- 20.171–0.652 0.195
HC: LPS+nicotine stimulated 0.337 20.125–0.678 0.136 0.503 0.0771–0.773 0.0202 0.266 20.201–0.634 0.244
doi:10.1371/journal.pone.0006285.t002
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Discussion
The interest in anti-bacterial peptides as an innate mechanism
of defence against bacteria has increased in recent years. In CD,
this interest has been intensified by the association between NOD2
mutations and decreased adefensin production from Paneth cells
[20–22], while a-defensins have also been found to be dysregu-
lated in UC [23]. HBD2 has been shown to be induced in the gut
[27,28] and upregulated in IBD [25,26]. More recently, HBD2
has been shown to be induced by IL12, IL23, and IL27 in
keratinocytes [43] and by IL17 in airway epithelium [44]. These
processes may also have relevance to IBD, as the IL17/IL23
pathway has been shown to be differentially regulated in CD and
UC [45].
The principal aims of the present study were to assess colonic
production of HBD2 protein, to compare these data with studies of
mRNA expression [25,26], and to assess the factors which may be
involved in the dysregulated responses observed. We have shown that
HBD2 mRNA expression was differentially increased with inflamma-
tion in specific colonic locations in CD and UC, and went on to show
that HBD2 protein production was increased by LPS but differentially
modulated by addition of nicotine in CD andUC. These latter findings
may have direct relevance to the clinical observation of the disparate
effect of smoking in these diseases [7,8,11].
In previous studies, Wehkamp et al [25] suggested that HBD2
mRNA was higher in UC than CD and induced with
inflammation in UC but not CD. However, in their study biopsies
were obtained at random from different areas of the colon, which
confound interpretation as our data showed HBD2 mRNA
expression differed according to location within the inflamed
colon. In the sigmoid colon we confirmed that HBD2 mRNA
expression is indeed higher in UC than CD, and our results also
demonstrate the same pattern of dysregulation at protein level.
These observations concur with other studies that have shown that
colonic expression of antimicrobial peptides is increased in UC
compared with CD [22,46]. The differential colonic expression in
UC paralleled that of other genes involved in innate immunity also
seen in this microarray dataset, especially the alpha defensins,
matrix metalloproteins 3 and 7, IL8, CCL20 and TLR4 [23].
We have gone on to address the issue as to whether the
dysregulated responses seen in IBD represent secondary, appro-
priate responses to disease processes or are part of the pathogenic
mechanisms. The increased expression of HDB2 in inflamed tissue
from UC patients was significantly higher than that seen in
controls. HBD2 was increased by LPS in IBD patients and
controls, confirming that HBD2 production is stimulated by
bacterial products [46–48]. As HBD2 production is reduced with
deletion of NF-kB binding sites in the promoter region of the
Figure 5. HBD2 production according to DEFB4 CNV. HBD2 production (mean+sem) from biopsies from CD, UC patients or controls,
unstimulated or stimulated with LPS or LPS+nicotine (denoted LN) and grouped according to copy number.
doi:10.1371/journal.pone.0006285.g005
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HBD2 gene [28], we investigated whether there were more genetic
polymorphisms at these sites in IBD patients than controls, but
found no differences. The augmented responses in IBD patients
require further investigation as to whether these are a direct
response to the local bacterial flora, as suggested by a recent study
that showed increased HBD2 mRNA in response to Staphylococ-
cus enterotoxin B in cultured duodenal explants [49], and/or
inflammation, or a resultant artefact of the dyregulated immunity
as part of IBD disease pathogenesis [43–45].
Our data add to the growing body of evidence in favour of
dysregulation of defensin production in IBD. We confirmed that
the production of HBD2 is increased with inflammation in UC but
not CD [25,26] and correlated with IL8 production. Wehkamp et
al found that HBD2 correlated with IL8 in inflamed but not
uninflamed biopsies from CD patients [25] but this was not
confirmed in our data. IL8 is a chemokine produced by epithelial
cells which is chemotactic for neutrophils and has been shown to
be increased in inflamed colonic tissue from UC patients [23]. The
correlation between levels of HBD2 and IL8 in UC and HC was
found when all biopsies were analysed together and remained
significant when LPS-stimulation was considered alone, suggesting
that HBD2 production in response to bacterial products might
lead to neutrophil accumulation as part of a wider inflammatory
response. IL8 and HBD2 production also correlated in unstimu-
lated biopsies from UC but not HC, suggesting that in UC patients
there may be some priming to bacterial motifs that would produce
an exaggerated defensin response [50].
We investigated whether smoking habit at sampling or
stimulation with nicotine alone had any effect on HBD2
production, but found no differences. However, an interesting
differential effect was seen from co-stimulation with LPS and
nicotine: LPS-induced HBD2 was maintained on addition of
nicotine in inflamed and uninflamed UC as well as inflamed CD
tissue but reduced by nicotine in uninflamed CD tissue. We
appreciate that the concentrations of nicotine used in our study
were higher than those found in blood or tissues [51–53]. Nicotine
is thought to have anti-inflammatory effects [54] but may also be
involved in promoting chronic inflammation [55]. A combination
of pre-existent inflammation and LPS stimulation may reduce the
anti-inflammatory nature of nicotine, though this might also
depend on the nature of both the inflammation and the time of
exposure to nicotine, as seen in animal models of the effects of
nicotine on systemic inflammation [56]. Evidence from the
respiratory literature has suggested that the function of a specific
defensin, HNP1, was modified in smokers but not non-smokers
leading to specific changes in its antibacterial properties [57,58].
While further investigation is required to confirm and strengthen
these data, it could be suggested that nicotine may affect the
production and/or function of HBD2.
Surprisingly, our results showed that production of HBD2
protein from patient biopsies in ex vivo culture was not associated
with the genomic copy number in CD, UC or controls. This is in
some apparent contrast with results of previous studies of mRNA,
which found direct correlations between copy number and
amount of mRNA in mucosal biopsies from IBD patients [33]
and in lymphoblastoid cell lines [29]. These differences could be
due to post-transcriptional or -translational modifications of
HBD2, or relate to the fact that HBD2 is an inducible gene
rather than constitutively expressed [25,59]. In a study of
induction of b-defensins in gingival keratinocytes [60] it was
found that HBD2 was consistently induced by IL1b and TNFa,
but that LPS and other cytokines might have an effect in different
individuals. In our biopsy cultures a variety of cytokines are
produced, which might in turn affect HBD2 protein production
[43,44,60]. While a simple relationship between genomic copy
number and protein production might be expected, a recent study
in psoriasis showed that serum HBD2 production was a reflection
of the disease activity in these patients and not the copy number
[61]. Thus the relative contributions of inflammation (local and
systemic), stimulus and copy number need to be teased out.
In conclusion, we have shown that HBD2 is differentially
expressed in CD and UC in response to colonic location and
inflammation. HBD2 production differed in CD and UC in
response to stimuli representative of the environmental factors of
bacterial stimulation and smoking products and may contribute to
and/or reflect the dysregulated innate immunity and disease
pathogenesis in IBD. We were unable to identify germline
mutations in the HBD2 gene that might be involved in disease-
associated dysregulation, but other epistatic or epigenetic factors
may be important.
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